Based on the paired specimens from the same patient (EGFR-L858R mutation) who initially benefitted from gefitinib treatment and then acquired resistance (Fig. 1a), we investigated the change in tumours before and after acquired EGFR-TKI resistance. Here, EGFR is linked to neoplasm.